Trigeminal Neuralgia - Pipeline Insight, 2024

This “Trigeminal Neuralgia- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Trigeminal Neuralgia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Trigeminal Neuralgia: Understanding

Trigeminal Neuralgia: Overview

Trigeminal Neuralgia is a chronic neuropathic pain disorder characterized by spontaneous and elicited paroxysms of electric shock-like or stabbing pain in a region of the face. The pain of trigeminal neuralgia most frequently affects the distribution of the second (maxillary) or third (mandibular) division of the trigeminal nerve, with the right side of the face affected more often than the left side. Three types of trigeminal neuralgia have been delineated: classical, secondary, and idiopathic. Bilateral trigeminal neuralgia is rare and should raise concern about facial neuralgia due to an underlying neurologic disease or a non-neurologic disorder affecting the cranium. The incidence of trigeminal neuralgia is higher among women than among men and increases with age.

Symptoms
The pain of Trigeminal Neuralgia can come in sharp spasms that feel like electric shocks. Pain generally occurs on one side of the face and may be brought on by sound or touch. Pain can be triggered by routine acts, including: brushing teeth, shaving, touching face, eating or drinking, speaking, a breeze on face etc.

Diagnosis
The diagnosis of trigeminal neuralgia is clinical and is based on three main criteria: pain restricted to the territory of one or more divisions of the trigeminal nerve; paroxysms of pain that are sudden, intense, and very short. Diagnosis will depend on the type and location of the pain and factors that trigger the pain.

Treatment
The anticonvulsant agents carbamazepine, in doses of approximately 200 to 1200 mg per day, and oxcarbazepine (300 to 1800 mg per day) have been considered the first-choice treatments for control of paroxysmal pain in patients with trigeminal neuralgia, regardless of the cause. Gabapentin, pregabalin, and antidepressant agents, which have been shown to be effective in the treatment of other neuropathic conditions characterized by continuous pain, may be tried as additional agents along with oxcarbazepine or carbamazepine. Microvascular decompression has become the surgical procedure that is now favored for most cases of trigeminal neuralgia that do not respond to medication.

Trigeminal Neuralgia- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Trigeminal Neuralgia pipeline landscape is provided which includes the disease overview and Trigeminal Neuralgia treatment guidelines. The assessment part of the report embraces, in depth Trigeminal Neuralgia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Trigeminal Neuralgia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Trigeminal Neuralgia R&D. The therapies under development are focused on novel approaches to treat/improve Trigeminal Neuralgia.

Trigeminal Neuralgia Emerging Drugs Chapters

This segment of the Trigeminal Neuralgia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Trigeminal Neuralgia Emerging Drugs

Vixotrigine: Biogen Vixotrigine (BIIB074) is a voltage and use-dependent sodium channel blocker. It is a centrally and peripherally acting small molecule. Vixotrigine, a non-opioid investigational pain drug, has the potential to address significant unmet medical needs of individuals living with chronic painful neuropathy. It is being developed by Biogen for the treatment of Trigeminal Neuralgia and is in Phase III ofdevelopment.

Rimegepant: Biohaven Pharmaceuticals Rimegepant is a Phase II calcitonin gene-related peptide receptor antagonists. It is being developed by Biohaven pharmaceuticals. The trail got initiated in June 2019 and is expected to get completed by October 2022 with expected 30 enrolled participants. (NCT03941834).

Trigeminal Neuralgia: Therapeutic Assessment

This segment of the report provides insights about the different Trigeminal Neuralgia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Trigeminal Neuralgia

There are approx. 10+ key companies which are developing the therapies for Trigeminal Neuralgia. The companies which have their Trigeminal Neuralgia drug candidates in the most advanced stage, i.e. phase III include, Biogen.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Trigeminal Neuralgia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Trigeminal Neuralgia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Trigeminal Neuralgia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Trigeminal Neuralgia drugs.

Trigeminal Neuralgia Report Insights

• Trigeminal Neuralgia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Trigeminal Neuralgia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Trigeminal Neuralgia drugs?
• How many Trigeminal Neuralgia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Trigeminal Neuralgia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Trigeminal Neuralgia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Trigeminal Neuralgia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Biogen
• Biohaven Pharmaceuticals
• Noema Pharma AG
• Pfizer

Key Products

• Vixotrigine
• Rimegepant
• Basimglurant

This product will be delivered within 1-3 business days.